Special Issue

Exploring Interventional Radiology: New Advances and Prospects

Message from the Guest Editor

This Special Issue of the Journal of Personalized *Medicine* is dedicated to interventional radiologists (IRs) seeking to showcase cutting-edge techniques, innovative approaches, and emerging challenges within the field of interventional radiology. We invite contributions that not only focus on novel treatments but also offer broader perspectives on the evolution and future of IR as a specialty. The scope of this Special Issue is not limited to therapeutic advancements. It encourages interdisciplinary and transversal contributions that address the holistic development of interventional radiology, including epidemiological studies, economic evaluations, and strategies for tackling the challenges facing the specialty today. We welcome research articles or reviews that provide new insights into optimizing clinical practice, as well as broader discussions on how to advance IR in a rapidly changing healthcare landscape. This Special Issue aims to serve as a platform for the IR community to share knowledge, explore new perspectives, and collectively shape the future of interventional radiology.

Guest Editor

Prof. Dr. Julien Frandon

Department of Medical Imaging, Nîmes University Hospital, University of Montpellier, 30029 Nimes, France

Deadline for manuscript submissions

30 June 2025



Journal of Personalized Medicine

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 4.1 Indexed in PubMed



mdpi.com/si/219849

Journal of Personalized Medicine MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 4.1 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

- 1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
- 2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC. Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).

